Drug profile · INN
methylphenidate hydrochloride
TUZULBY
methylphenidate hydrochloride (TUZULBY) is a dopamine transporter inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — methylphenidate hydrochloride
- US status
- approved
- Class
- Nervous system (N06)
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
methylphenidate hydrochloride (TUZULBY) is a dopamine transporter inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dopamine transporter inhibitor
Primary target: Sodium-dependent dopamine transporter
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is methylphenidate hydrochloride?
methylphenidate hydrochloride (TUZULBY) is a dopamine transporter inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for methylphenidate hydrochloride?
TUZULBY is a marketed brand name for methylphenidate hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of methylphenidate hydrochloride?
methylphenidate hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.